Immunovant, Inc. (IMVT) — Total Assets
| Fiscal Year | Total Assets | Change YoY |
|---|---|---|
| 2026 | $957.01M | +23.3% |
| 2025 | $776.22M | +16.5% |
| 2024 | $666.37M | +64.2% |
| 2023 | $405.84M | -21.3% |
| 2022 | $515.56M | +25.0% |
| 2021 | $412.49M | +277.1% |
| 2020 | $109.39M | +691.1% |
| 2019 | $13.83M | — |
| Fiscal Year | Total Assets | Change YoY |
|---|---|---|
| 2026 | $957.01M | +23.3% |
| 2025 | $776.22M | +16.5% |
| 2024 | $666.37M | +64.2% |
| 2023 | $405.84M | -21.3% |
| 2022 | $515.56M | +25.0% |
| 2021 | $412.49M | +277.1% |
| 2020 | $109.39M | +691.1% |
| 2019 | $13.83M | — |